Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042650 · ClinicalTrials.gov registry record · NA
Intensive Referral to Reduce Smoking in Probationers
A NA study, sponsored by University of Nebraska.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT03042650: Completed NA study, sponsored by University of Nebraska.
NCT03042650 is a NA study that has completed, run by University of Nebraska. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03042650, a NA study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Intensive Referral Intervention increases motivation to quit cigarette smoking and quitting-related behaviors in probationers and also to determine if Intensive Referral Intervention improves short-term substance use outcomes in probationers with substance use disorder.
Primary Outcome
Increased Motivation to quit cigarette smoking in probationers as indicated by change in Fagerstrom Test for Nicotine Dependence
Interventions
- BEHAVIORAL Intensive Referral Intervention Group
- BEHAVIORAL Standard Practice Facilitated Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2019-09-27 |
| Phase | NA |
What the finished NCT03042650 record still lists
NCT03042650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Intensive Referral Intervention Group is the first listed.
NCT03042650 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03042650 about?
NCT03042650 is a clinical study titled "Intensive Referral to Reduce Smoking in Probationers". The purpose of this study is to determine if Intensive Referral Intervention increases motivation to quit cigarette smoking and quitting-related behaviors in probationers and also to determine if Intensive Referral Intervention improves short-term substance use outcomes in probationers with substanc...
What is the current status of trial NCT03042650?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2016-07-01. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03042650?
The interventions under investigation include: Intensive Referral Intervention Group (BEHAVIORAL), Standard Practice Facilitated Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT03042650?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03042650's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI